Q2 net sales rose 34% year-over-year to SEK 239 million, with strong growth in thoracic and abdominal segments and robust profitability. Regulatory progress and manufacturing scale-up support continued expansion, while positive cash flow and liquidity enable ongoing investments.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.